Abstract
Objective: To discuss the integration of Intensive Behavioral Therapy for Obesity (IBT) in conjunction with pharmacotherapy (Liraglutide) and changes in lifestyle for the treatment of obese patients. Bibliographic review: Obesity is a chronic inflammatory disease that has increased significantly in recent years and represents an increased risk factor for type 2 diabetes, cardiovascular disease, cancer and sleep apnea. The treatment of obesity must be carried out individually and in a multidisciplinary way, integrating IBT with pharmacotherapy, in cases of BMI> 30 kg / m² or with BMI> 27 kg / m² with associated comorbidity. Amongthe existing drugs similar to GLP-1, liraglutide is one of the most well-known and widespread substances in association with IBT, doubling the average weight loss (11.5%) in obese patients in the short term and when including food readjustment and exercise, long-term improvements were observed. Final considerations Liraglutide is an important drug to maintain and induce weight loss in obese patients, however it is a subcutaneous and expensive drug.